Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eperisone versus baclofen in amyotrophic lateral sclerosis
2010-020257-13Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eperisone in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Azienda Ospedaliero-Universitaria. Primary endpoints: Number of therapeutic failures and Improvement in spasticity. Started Jul 2010; status: terminated.
02
Drugs
eperisone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2010-020257-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020257-13.